Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Sitagliptin Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN110540975B reveals high-efficiency biocatalytic route for sitagliptin precursors, offering superior stereoselectivity and reduced environmental impact for pharma supply chains.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediate synthesis, offering superior conversion rates and cost reduction in pharmaceutical intermediates manufacturing.
Patent CN111549008B reveals a novel AcATA mutant for sitagliptin intermediates. Achieves 90% conversion with superior purity and reduced environmental impact for pharma supply chains.
This patent details a novel biocatalytic route for sitagliptin intermediates offering high purity and yield. It enables significant cost reduction and supply chain reliability for pharmaceutical manufacturing partners.
Patent CN113801903B reveals enzymatic route for sitagliptin intermediate offering high purity and supply chain stability for global API manufacturers.
Patent CN106995807A enables high-purity Sitagliptin intermediate synthesis via recombinant transaminase, offering supply chain stability and cost efficiency.
Novel industrial route for 2,4,5-trifluorophenylacetic acid using 2,4-dichlorotoluene. High yield, cost-effective manufacturing for DPP-4 inhibitor intermediates.
Novel Pd-catalyzed synthesis for Sitagliptin intermediate. High ee value, reduced waste, scalable production for pharma supply chains.
Novel patent CN105017081A offers high-yield Sitagliptin intermediate synthesis. Reduces cost and improves supply chain reliability for pharmaceutical manufacturing.
Novel low-cost route for Sitagliptin intermediates via chiral resolution. Reduces catalyst costs and simplifies scale-up for API manufacturing.
Patent CN115819260B reveals a novel synthesis route for sitagliptin intermediates offering cost reduction and high purity for pharmaceutical supply chains.
Patent CN111471003A details a novel Negishi coupling route for sitagliptin intermediates, offering high purity and reduced steps for reliable pharmaceutical intermediate supply chains.
Novel magnesium-catalyzed asymmetric allylation for Sitagliptin intermediate. Reduces cost and improves supply chain reliability for pharmaceutical manufacturers.
Novel hydrogenation process reduces noble metal usage and improves purity for sitagliptin manufacturing, offering significant cost and supply chain advantages.
Patent CN104140430B enables recycling of S-isomers via halogenation. Reduces waste and cost for pharmaceutical intermediate manufacturing supply chains.
Novel nitrogen-containing formyl catalyst method for sitagliptin intermediate. High yield, mild conditions, reduced costs for pharmaceutical manufacturing supply chains.
Novel Mo/Cu co-catalyzed method offers high yields and mild conditions for scalable production of key heterocyclic building blocks.